WCLC 2022 | Lung cancer disparities in molecular testing and therapy outcome in Hispanics in Latin America

Disparities in diagnosis and clinical outcomes of Hispanic patients with lung cancer compared with Non-Hispanic White patients are well-documented, whereby Hispanics have disadvantages in terms of access to care, health insurance, cultural differences, and immigration status. Despite this, Hispanics have a better overall-survival (OS) than other minorities, which created the Hispanic Health Paradox (HHP). Luis Raez, MD, FACP, FCCP, Memorial Cancer Institute/Memorial Healthcare System, Miami, FL, discusses a review on recent publications in Hispanics, which demonstrated significant disparities in Hispanics with lung cancer care exist in the US and Latin America. Although Hispanics have a biological advantage not yet understood, the lack in biomarker access and targeted therapy as a result of social determinants of health, the potential biological benefits are eliminated. This interview took place at the IASLC 2022 World Conference on Lung Cancer congress in Vienna, Austria.